Recent studies have revealed that long non-coding RNAs (lncRNAs) are involved in different physiological processes and human diseases. However, to date, the function and overall clinical significance of the vast majority of lncRNAs in breast cancer remain largely unexplored. Here, we focused on LINC00310 by interrogating the breast invasive carcinoma data set of the Cancer Genome Atlas (TCGA). The results showed that LINC00310 was increased as breast cancer progressed, and the dereg- cancer is considered as a complex disease with high heterogeneity, exhibiting wide variability in prognostic pattern and treatment response. 3-6 Therefore, it is urgently necessary to identify novel biomarkers that may not only predict the biological behaviour and clinical outcome, but also improve design of treatment protocols and development of novel therapeutic candidates for breast cancer.
potential. They are proposed to constitute major proportion of human cellular transcripts. 7, 8 Once considered to be transcriptional noise, lncRNAs are less well characterized than small non-coding microRNAs. [9] [10] [11] However, increasing evidence suggests that lncRNAs play important roles in various processes and provide a new insight into cancer biology. [12] [13] [14] Like protein-coding genes, lncRNAs can function as oncogenic or tumour suppressor genes and regulate target gene expression at multiple levels, including transcriptional and post-transcriptional levels, 15 thus affecting one or more of the cancer hallmarks, such as cell growth, apoptosis, differentiation, invasion and metastasis. 16, 17 Abnormally expressed lncRNAs have been observed in various types of cancers, including breast cancer. 18, 19 For instance, lncRNA HOTAIR (Hox transcript antisense intergenic RNA) is overexpressed in patients with breast cancer, and its deregulation is correlated with enhanced breast cancer metastasis. 20 Up-regulation of lncRNA BC200 contributes to breast cancer pathogenesis and progression by restraining apoptotic cell death due to its ability to regulate Bcl-xL expression. 21 However, the function and overall clinical significance of the vast majority of lncRNAs in breast cancer remain largely undetermined. Moreover, recent studies have demonstrated that lncRNAs exhibit greater expression restriction, and several lncRNAs have shown the potential as biomarkers for cancer diagnosis and prognosis. 22, 23 Thus, there is an urgent need to explore functional roles of novel lncRNAs in breast cancer, which may provide a new molecular option for its diagnosis and prognosis.
In this study, LINC00310 was identified to be associated with prognosis of patients with breast cancer by interrogating the breast invasive carcinoma data set of the Cancer Genome Atlas (TCGA) at cBioPortal. We then characterized LINC00310 by knockout (KO) cell models and revealed that LINC00310 played an oncogenic role in breast cancer both in vitro and in vivo. Furthermore, we detected the expression of LINC00310 in serum samples of patients with breast cancer and evaluated its clinical significance as a potential biomarker for breast cancer diagnosis.
| MATERIALS AND METHODS

| Reagents
Primary antibodies used in this study were obtained from different sources as follows: c-Myc was purchased from Abcam (Cambridge, MA, USA), and a-tubulin and GAPDH were obtained from Protein 
| Plasmid construction
Respective DNA fragments were amplified by PCRs for cloning purpose using Phusion enzyme from Thermo Fisher Scientific (Pittsburgh, PA, USA). Dual gRNAs targeting LINC00310 were designed based on CHOPCHOP (https://chopchop.rc.fas.harvard.edu/), and their sequences were listed in Table S1 . For dual gRNA and the corresponding donor cloning, the same method recently developed in our laboratory was used. 25 and LINC00310-right-Sal I-3.1 (right arm), while human genomic DNA was used as a template. These two fragments were sequentially cloned into donor vector carrying marker genes (GFP and PU, the puromycin resistance gene) at Spe I and Sal I sites. To generate LINC00310
expression construct for rescue experiments, the entire LINC00310 sequence was amplified by PCR using primers LINC00310-R1-5.1 and LINC00310-Not1-3.1 and then cloned into pCDH-MSCV-EF1-GFP-T2A-Pu (System Bioscience). All amplified fragments were verified by DNA sequencing. All the primers used in plasmid construction were listed in Table S1 . 
| MTT assay
MTT assay was conducted to check the effect of LINC00310 on cell growth as previously described. 27 Briefly, LM-4142 cells were seeded into 96-well plates at a density of 1000 cells/well, and the measurement was performed for 0-4 days after seeding.
| Clonogenic assay
To assess the colony-forming ability of the cells, LM-4142 cells were seeded into 6-well plates at a density of 1000 cells/well. After 10 days, colonies were fixed and stained with 0.1% crystal violet before counting. and c-Myc were specifically detected using the SYBR Green method with primers listed in Table S1 . GAPDH or b-actin was used as an internal control. Delta-delta Ct values were used to calculate their relative expressions as previously described. 
| RNA isolation, RT-PCR and qRT-PCR
| Western blot analysis
Cells were harvested, and proteins were extracted from cells and quantified using Bio-Rad Protein Assay Dye Reagent (Bio-Rad, Hercules, CA, USA). Western blot analysis was performed as previously described. and tumour volume was calculated by the formula as follows: vol- 
| Statistical analysis
| RESULTS
| LINC00310 is associated with the progression and survival outcome of breast cancer
As deep sequencing becomes a commonly used tool to provide more valuable information, the expression data (RNA-Seq) of LINC00310
were searched in breast cancer based on the Onco Query Language criteria "EXP ≥ 2" from the Cancer Genome Atlas (TCGA) data set at the cBioPortal for Cancer Genomics. We found that the alteration of LINC00310 with RNA expression occurred at a frequency of 4% in total of 1110 samples ( Figure S1 ). The expression of LINC00310 was significantly higher in patients with advanced breast cancer compared with the patients with stage I breast cancer ( Figure 1A ), indicating that it might be involved in the progression of breast cancer. Next, we further determined whether deregulation of LINC00310 could predict clinical outcome of patients. We found that the up-regulation of LINC00310 was significantly associated with patients' survival (P < .05) ( Figure 1B,C) . Especially, patients with high LINC00310 expression had a significantly poorer disease-free survival compared with those with low LINC00310 expression ( Figure 1C ). In addition, we profiled breast cancer cDNA arrays from
OriGene by qRT-PCR, and the results showed that the LINC00310 expression was elevated in breast cancer tissues compared with the normal tissues ( Figure 1D ). Taken together, these findings suggest that LINC00310 may play an oncogenic role and can be explored as a prognostic biomarker for breast cancer.
| Generation of LINC00310 KO with CRISPR/
Cas9 system using a dual gRNA approach
To better characterize the oncogenic role of LINC00310, we further checked its expression in different cell lines and found that LINC00310 was up-regulated in breast cancer cell line LM-4142 compared with the non-malignant HMLE cells (Figure 2A ). Therefore, we took advantage of a dual gRNA approach with CRISPR/Cas9 system to knock out LINC00310 in LM-4142 cells. These two gRNAs were located at the 5ʹ and 3ʹ extremities of the LINC00310 gene, enabling us to delete the entire gene ( Figure S2 ). To identify KO clones of LINC00310, we initially screened hundreds of randomly picked single colonies by genomic PCR. Firstly, we amplified the dual gRNA-targeted region using primers derived from outside of two gRNAs ( Figure S2 ) and four (#94, #156, #44 and #117) colonies showed deletion bands ( Figure 2B ). Genomic PCR using primers inside of the targeting sites was then carried out. As shown in Fig- ure 2C, it is evident that no PCR product was detected in KO #94,
suggesting that it was a complete KO clone. However, there were still inside bands in the other three clones (#156, #44 and #117),
indicating that they were all partially KO clones. Consistent with these results, although the sensitive qRT-PCR caused some background amplification, we found that the LINC00310 expression was substantially decreased ( Figure 2D ). Finally, we selected two clones (#94 and #44) for further characterization.
| LINC00310 KO inhibits tumour cell growth and c-Myc expression in vitro
We next determined the biological consequence of LINC00310 ablation in tumorigenesis. As expected, MTT assays showed that LINC00310 KO significantly reduced the cell growth ( Figure 3A) .
Meanwhile, we found that the number of colonies was much smaller in LINC00310 KO cells compared with the vector control as detected by clonogenic assays ( Figure 3B ). These results provide evidence that LINC00310 affects tumour cell growth and proliferation, and thus, LINC00310 may serve as a potential oncogene.
To demonstrate how LINC00310 impacts cell growth and proliferation, we attempted to analyse a number of genes such as Myc, which play essential roles in breast tumorigenesis using TCGA data set from the cBioPortal for Cancer Genomics. Spearman correlation analysis revealed that the Myc protein expression was significantly associated with LINC00310 level in breast cancer (P = .0081) (Figure 3C) . Therefore, we identified the effect of LINC00310 on c-Myc expression. As shown in Figure 3D , qRT-PCR data showed that LINC00310 KO decreased the c-Myc mRNA expression. At the protein level, we also observed a significant inhibition of c-Myc in both LINC00310 KO clones ( Figure 3E ). These results suggest that 
| LINC00310 KO inhibits tumour growth and c-
Myc expression in vivo
We then checked the effect of LINC00310 ablation on primary tumour growth using nude mouse xenograft models. The complete KO clone (KO #94) and vector control cells were selected to inject into the mammary fat pads of female nude mice. In consistent with in vitro results, we found that LINC00310 KO inhibited tumour growth compared with the vector control ( Figure 4A ). Moreover, the LINC00310 KO also decreased tumour weight ( Figure 4B , left).
There was an obvious visual difference in the tumour size between the two groups ( Figure 4B, right) , suggesting the role of LINC00310 in primary tumour growth of breast cancer. As expected, we found little expression of LINC00310 in LINC00310 KO tumours (Figure 4C ). Tumours derived from LINC00310 KO exhibited lower cMyc expression at both the mRNA ( Figure 4D ) and protein levels ( Figure 4E ) than those derived from vector control, further indicating that LINC00310 played a critical role in tumour growth through regulation of c-Myc.
| Re-expression of LINC00310 restores tumour growth and c-Myc expression
To further confirm whether the growth inhibition was caused by the c-Myc down-regulation which was regulated by LINC00310 KO, we performed the rescue experiments to re-express LINC00310 in complete KO clone (KO #94) ( Figure 5A ). As expected, MTT assays
showed that re-expression of LINC00310 in the KO cells significantly increased the cell growth ( Figure 5B ). Consistent with this result, the number of colonies was restored by LINC00310 reexpression compared with the vector control as detected by clonogenic assays ( Figure 5C ). Importantly, ectopic expression of LINC00310 increased the c-Myc expression at both the mRNA and protein levels ( Figure 5D ,E). Taken together, these findings further indicate that LINC00310 may regulate the c-Myc expression, contributing to its oncogenic role.
| Diagnostic performance of serum LINC00310 expression
Given that LINC00310 might play an oncogenic role in breast cancer, we tried to evaluate whether LINC00310 could be used as a potential biomarker for diagnosis of breast cancer. We determined the expression of LINC00310 by qRT-PCR, using 95 serum samples, including 48 patients with breast cancer and 47 healthy controls.
The results showed that serum LINC00310 expression in patients with breast cancer was significantly up-regulated in comparison with healthy controls ( Figure 6A ). An ROC curve was constructed based on the above findings to assess the diagnostic value of LINC00310.
The results demonstrated that LINC00310 had a strong capability of distinguishing patients with breast cancer from healthy individuals, with an AUC of 0.828 (95% confidence interval [CI] = 0.737-0.898) ( Figure 6B ). When the cut-off value was set to the optimal point (1.402), the sensitivity and specificity were 77.08% and 87.23%, respectively. These findings suggest that serum LINC00310 Recently, circulating RNAs in blood have been an emerging field for non-invasive diagnostic applications. 46 Several studies have suggested that circulating lncRNAs can be protected from endogenous RNase activity, making them highly stable and suitable as markers of the non-invasive analysis for patient samples. 47, 48 In the present study, we found that the LINC00310 expression in serum of patients with breast cancer was significantly up-regulated compared with the healthy controls. ROC curve analysis demonstrated that LINC00310 had a powerful capability of distinguishing patients with breast cancer from healthy individuals ( Figure 6 ). These findings underscore the potential significance of LINC00310 in serving as a biomarker for the diagnosis of breast cancer. In this regard, our study was consistent with recent reports on lncRNAs as potential circulating biomarkers for breast cancer. For example, plasma lncRNA GAS5 is significantly decreased in the postoperative samples compared with paired preoperative samples, indicating that GAS5 may have the potential to assess the surgical effects for breast cancer. 49 Of interest, circulating DNA has been found to be the major form of HOTAIR-derived fragment in serum, and circulating HOTAIR DNA may be a potential marker for distinguishing breast cancer patients from healthy individuals. 50 Taken together, these findings may generate a great enthusiasm in exploring the potential of circulating lncRNAs as minimally invasive markers. However, as these studies generally focus on circulating individual cancer-specific lncRNA as cancer biomarkers, a caveat may be that a single lncRNA may not be sufficient to serve as a reliable biomarker due to the complex pathophysiology of cancer initiation and progression. Therefore, simultaneous evaluation of tumour-associated circulating lncRNA panel may F I G U R E 6 Diagnostic performance of serum LINC00310 expression. A, Relative expression analysis of LINC00310 in serum of patients with breast cancer (tumour) and healthy controls (Normal) using qRT-PCR. B, ROC curve analysis for the detection of breast cancer using serum LINC00310. **P < .01 LI ET AL.
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increase the sensitivity and specificity of diagnosis and prognosis in breast cancer. Towards this direction, one recent study using a small cohort has demonstrated that a three-lncRNA signature, including ANRIL, HIF1A-AS2 and UCA1, can serve as diagnostic markers for differentiating between triple-negative and non-triple-negative breast cancer. 51 
